Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

Welcome to APCCC 2021

Prof Silke Gillessen and Prof Aurelius Omlin

Welcome to APCCC 2021 ( Prof Silke Gillessen and Prof Aurelius Omlin )

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after...

Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron...

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )

ESMO 2021 Roundup

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2021 Roundup ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed...

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

$Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )$

OncoAlert and ecancer - ESMO 2021 Day 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Dr Neal Shore and Prof Fred Saad

PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with...

Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post...

Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer ( Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Novel therapies in multiple myeloma

Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA

Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25%...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic...

Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer ( Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom )

More from ecancer